# US 2008/0306008 A1 · Peptides for Use in the Treatment of Obesity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306008 A1
- Document ID: US20080306008A1
- Status: Published application
- Kind: A1
- Application number: 11/666,800
- Filed: 2005-11-04
- Published: 2008-12-11
- Earliest claimed: 2004-11-04
- Assignees: Nova Nordisk A/S
- Inventors: Ulrich Sensfuss; Leif Christensen
- Web page: https://patentgrep.com/patent/US20080306008A1

## CPC

- C07K 7/56: the cyclisation not occurring through 2,4-diamino-butanoic acid
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 15/10: for impotence
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 35/00: Antineoplastic agents
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/68: Melanocyte-stimulating hormone [MSH]
- C07K 14/72: for hormones {(for neuromediators C07K14/70571)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

## Claims

### Claim 1

A compound of formula Ia, Ib or Ic:
R1—S-Z1-Z2-Z3-c[X1-X2-X3-Arg-X4-X5]N(R′)2 [Ia]
R1—S-Z2-Z3-c[X1-X2-X3-Arg-X4-X5]N(R′)2 [Ib]
R1—S-Z1-c[X1-X2-X3-Arg-X4-X5]N(R′)2 [Ic]
wherein R1 represents a straight-chain, branched and/or cyclic C14-20alkanoyl, C14-20alkenoyl or C14-20alkynoyl which may optionally be substituted with one or more substituents selected from halogen, hydroxyl and aryl, or R1 represents C9-17—C(O)—NH—S(O)2—(CH2)3—C(O)—;
S represents a glycolether-based structure according to one of the formulas IIa-IIe
Z1 and Z2 independently represent Gly, Ser, Thr, Gln, Asn, His, homoArg, Arg, Lys, Dab, Dap or Orn;
Z3 represents Ala, Val, Leu, Ile, Met or Nle;
X1 represents Glu, Asp, Cys, homoCys, Pen, Lys, Orn, Dab or Dap;
X2 represents His, Cit, Dab, Dap, Cgl, Cha, Val, Ile, tBuGly, Leu, Tyr, Glu, Ala, Nle, Met, Met(O), Met(O2), Gln, Gln(alkyl), Gln(aryl), Asn, Asn(alkyl), Asn(aryl), Ser, Thr, Cys, Pro, Hyp, Tic, 2-PyAla, 3-PyAla, 4-PyAla, (2-thienyl)alanine, 3-(thienyl)alanine, (4-thiazolyl)Ala, (2-furyl)alanine, (3-furyl)alanine or Phe, wherein the phenyl moiety of said Phe is optionally substituted with a substituent selected among halogen, hydroxy, alkoxy, nitro, benzoyl, methyl, trifluoromethyl, amino and cyano;
X3 represents D-Phe, wherein the phenyl moiety in D-Phe may optionally be substituted with one or more substituents selected among halogen, hydroxy, alkoxy, nitro, methyl, trifluoromethyl and cyano;
X4 represents Trp, 2-NaI, a (3-benzo[b]thienyl)alanine residue or a (S)-2,3,4,9-tetrahydro-1H-β-carboline-3-carboxylic acid residue;
X5 represents Glu, Asp, Cys, homoCys, Pen, Lys, Om, Dab or Dap;
wherein X1 and X5 are joined, rendering the compound of formula Ia, Ib or Ic cyclic, either via a disulfide bridge deriving from X1 and X5 both independently being Cys, homoCys or Pen, or via an amide bond formed between a carboxylic acid in the side-chain of X1 and an amino group in the side chain of X5, or between a carboxylic acid in the side-chain of X5 and an amino group in the side-chain of X1;
each R′ independently represents hydrogen or C1-6alkyl, which may optionally be substituted with one or more amino or hydroxy;
with the proviso that the compound of formula Ia, Ib or Ic is not
2-[2-(octadecanoylamino)ethoxy]ethoxyacetyl-Nle-c[Glu-Hyp-D-Phe-Arg-Trp-Lys]-NH2,
3-(2-{2-[2-(2-(hexadecanoylamino)ethoxy)ethoxy]ethoxy}ethoxy)propionyl-Nle-c[Glu-Hyp-D-Phe-Arg-Trp-Lys]-NH2,
2-[2-(hexadecanoylamino)ethoxy]ethoxyacetyl-His-Ser-Nle-c[Glu-Hyp-D-Phe-Arg-Trp-Lys]-NH2,
2-[2-(hexadecanoylamino)ethoxy]ethoxyacetyl-Arg-Ser-Nle-c[Glu-Hyp-D-Phe-Arg-Trp-Lys]-NH2 or
2-[2-(hexadecanoylamino)ethoxy]ethoxyacetyl-Gln-Ser-Nle-c[Glu-Hyp-D-Phe-Arg-Trp-Lys]-NH2;
and pharmaceutically acceptable salts, prodrugs and solvates thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R1 is C14-18alkanoyl.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R1 is 4-(C14-18alkanoylsulfamoyl)butanoyl.

### Claim 4 (depends on 3)

The compound according to claim 3, wherein R1 is 4-(hexadecanoylsulfamoyl)butanoyl.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein S has a structure selected among formulas IIa, IId and IIe.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein Z3 is Nle.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein Z2 is Ser, Thr, Dab or Dap.

### Claim 8 (depends on 7)

The compound according to claim 7, wherein Z2 is Ser or Dab.

### Claim 9 (depends on 1)

The A compound according to claim 1, wherein Z1 is His, Gln, Arg, homoArg, Lys, Orn, Dab or Dap.

### Claim 10 (depends on 9)

The A compound according to claim 9, wherein Z1 is His, Gln or Arg.

### Claim 11 (depends on 1)

The A compound according to claim 1 wherein
R1 is C14-18alkanoyl or 4-(hexadecanoylsulfamoyl)butanoyl;
Z1, if present, is His, Arg, homoArg, Lys, Gln, Asn, Om, Dab or Dap;
Z2, if present, is Ser, Thr, Dab or Dap;
Z3 is Nle;
X1 is Glu, Asp or Cys;
X2 is Ser, Hyp, Cit, Dap, Asn, Gln or (4-thiazolyl)Ala;
X3 is D-Phe;
X4 is Trp;
X5 is Lys when X1 is Glu or Asp, or X5 is Cys when X1 is Cys; and
N(R′)2 is NH2.

### Claim 12 (depends on 11)

The compound according to claim 11, wherein Z1, if present, is His, Arg or Gln.

### Claim 13 (depends on 11)

The A compound according to claim 11, wherein Z2, if present, is Ser, Thr or Dab.

### Claim 14 (depends on 12)

The A compound according to claim 12, wherein X2 is Ser, Hyp, Asn, Gln or Dap.

### Claim 15 (depends on 14)

The compound according to claim 14, wherein X2 is Hyp.

### Claim 16 (depends on 14)

The compound according to claim 14, wherein X2 is Asn.

### Claim 17 (depends on 14)

The compound according to claim 14, wherein X2 is Gln.

### Claim 18 (depends on 14)

The compound according to claim 14, wherein X2 is Dap.

### Claim 19 (depends on 11)

The compound according to claim 11, wherein S has a structure selected among formulas IIa, IId and IIe.

### Claim 20 (depends on 1)

The compound according to claim 1, selected from the group consisting of:
2-[2-(hexadecanoylamino)ethoxy]ethoxyacetyl-His-Ser-Nle-c[Glu-Asn-D-Phe-Arg-Trp-Lys]-NH2,
2-[2-(hexadecanoylamino)ethoxy]ethoxyacetyl-Gln-Ser-Nle-c[Glu-Asn-D-Phe-Arg-Trp-Lys]-NH2,
2-[2-(2-{2-[2-(tetradecanoylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxyacetyl-Nle-c[Glu-Asn-D-Phe-Arg-Trp-Lys]-NH2,
2-[2-(2-{2-[2-(tetradecanoylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxyacetyl-Nle-c[Glu-Hyp-D-Phe-Arg-Trp-Lys]-NH2,
3-[2-(2-{2-[2-(hexadecanoylamino)ethoxy]ethoxy}ethoxy)ethoxy]propanoyl-His-Dab-Nle-c[Glu-Hyp-D-Phe-Arg-Trp-Lys]-NH2,
2-[2-(2-{2-[2-(hexadecanoylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxyacetyl-Nle-c[Glu-Dap-D-Phe-Arg-Trp-Lys]-NH2,
2-[2-(hexadecanoylamino)ethoxy]ethoxyacetyl-Arg-Ser-Nle-c[Glu-Asn-D-Phe-Arg-Trp-Lys]-NH2,
2-[2-(hexadecanoylamino)ethoxy]ethoxyacetyl-His-Ser-Nle-c[Asp-Hyp-D-Phe-Arg-Trp-Lys]-NH2,
2-[2-(2-{2-[2-(tetradecanoylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxyacetyl-Dab-Nle-c[Glu-Asn-D-Phe-Arg-Trp-Lys]-NH2,
2-[2-(2-{2-[2-(tetradecanoylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxyacetyl-Nle-c[Glu-Ser-D-Phe-Arg-Trp-Lys]-NH2,
2-[2-(2-{2-[2-(tetradecanoylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxyacetyl-Nle-c[Glu-Gln-D-Phe-Arg-Trp-Lys]-NH2,
2-[2-(2-{2-[2-(tetradecanoylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxyacetyl-Nle-c[Glu-Cit-D-Phe-Arg-Trp-Lys]-NH2,
2-[2-(4-(hexadecanoylsulfamoyl)butanoylamino)ethoxy]ethoxyacetyl-Nle-c[Glu-Dap-D-Phe-Arg-Trp-Lys]-NH2,
{2-[2-(2-(hexadecanoylamino)ethoxy)ethoxy]ethylcarbamoyl}methoxyacetyl-Ser-Nle-c[Asp-Asn-D-Phe-Arg-Trp-Lys]-NH2,
{2-[2-(2-(tetradecanoylamino)ethoxy)ethoxy]ethylcarbamoyl}methoxyacetyl-Ser-Nle-c[Asp-Hyp-D-Phe-Arg-Trp-Lys]-NH2,
4-{2-[2-(2-(octadecanoylamino)ethoxy)ethoxy]ethylcarbamoyl}butanoyl-Dab-Nle-c[Asp-Hyp-D-Phe-Arg-Trp-Lys]-NH2,
4-{2-[2-(2-(tetradecanoylamino)ethoxy)ethoxy]ethylcarbamoyl}butanoyl-Thr-Nle-c[Glu-Gln-D-Phe-Arg-Trp-Lys]-NH2,
3-(2-{2-[2-(2-(hexadecanoylamino)ethoxy)ethoxy]ethoxy}ethoxy)propionyl-Nle-c[Glu-Dap-D-Phe-Arg-Trp-Lys]-NH2,
2-[2-(4-(hexadecanoylsulfamoyl)butanoylamino)ethoxy]ethoxyacetyl-His-Ser-Nle-c[Glu-Hyp-D-Phe-Arg-Trp-Lys]-NH2,
2-[2-(4-(tridecanoylsulfamoyl)butanoylamino)ethoxy]ethoxyacetyl-His-Ser-Nle-c[Glu-Hyp-D-Phe-Arg-Trp-Lys]-NH2, and
2-[2-(4-(hexadecanoylsulfamoyl)butanoylamino)ethoxy]ethoxyacetyl-His-Ser-Nle-c[Cys-Hyp-D-Phe-Arg-Trp-Cys]-NH2.

### Claim 21 (depends on 1)

A method of delaying the progression from IGT to type 2 diabetes, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1, optionally in combination with one or more additional therapeutically active compounds.

### Claim 22 (depends on 1)

A method of delaying the progression from type 2 diabetes to insulin-requiring diabetes, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1, optionally in combination with one or more additional therapeutically active compounds.

### Claim 23 (depends on 1)

A method of treating obesity or preventing overweight, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1, optionally in combination with one or more additional therapeutically active compounds.

### Claim 24 (depends on 1)

A method of regulating appetite, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1, optionally in combination with one or more additional therapeutically active compounds.

### Claim 25 (depends on 1)

A method of inducing satiety, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1, optionally in combination with one or more additional therapeutically active compounds.

### Claim 26 (depends on 1)

A method of preventing weight gain after successfully having lost weight, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1, optionally in combination with one or more additional therapeutically active compounds.

### Claim 27 (depends on 1)

A method of increasing energy expenditure, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1, optionally in combination with one or more additional therapeutically active compounds.

### Claim 28 (depends on 1)

A method of treating a disease or state related to overweight or obesity, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1, optionally in combination with one or more additional therapeutically active compounds.

### Claim 29 (depends on 1)

A method of treating bulimia, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1, optionally in combination with one or more additional therapeutically active compounds.

### Claim 30 (depends on 1)

A method of treating binge-eating, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1, optionally in combination with one or more additional therapeutically active compounds.

### Claim 31 (depends on 1)

A method of treating a disease or state selected from atherosclerosis, hypertension, diabetes, type 2 diabetes, impaired glucose tolerance (IGT), dyslipidemia, coronary heart disease, gallbladder disease, gall stone, osteoarthritis, cancer, sexual dysfunction and risk of premature death, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1, optionally in combination with one or more additional therapeutically active compounds.

### Claim 32 (depends on 1)

A method of treating, in an obese patient, a disease or state selected from type 2 diabetes, impaired glucose tolerance (IGT), dyslipidemia, coronary heart disease, gallbladder disease, gall stone, osteoarthritis, cancer, sexual dysfunction and risk of premature death, comprising administering to an obese patient in need thereof an effective amount of a compound according to claim 1, optionally in combination with one or more additional therapeutically active compounds.

### Claim 33 (depends on 21)

A method according to claim 21, wherein said additional therapeutically active compound is selected from antidiabetic agents, antihyperlipidemic agents, antiobesity agents, antihypertensive agents and agents for the treatment of complications resulting from, or associated with, diabetes.

### Claim 34 (depends on 1, 21)

A method according to claim 21, wherein said compound according to claim 1 is administered to said patient in a unit dosage form comprising from about 0.05 mg to about 1000 mg of said compound.

### Claim 35 (depends on 1)

A method of activating MC4 in a subject, the method comprising administering to said subject an effective amount of a compound according to claim 1,

### Claim 36 (depends on 1, 21)

A method according to claim 21, wherein said compound according to claim 1 is administered parenterally by nasal, pulmonary or sublingual administration.

### Claim 37

(canceled)

### Claim 38 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1.

### Claim 39

(canceled)

### Claim 40 (depends on 22)

A method according to claim 22, wherein said additional therapeutically active compound is selected from antidiabetic agents, antihyperlipidemic agents, antiobesity agents, antihypertensive agents and agents for the treatment of complications resulting from, or associated with, diabetes.

### Claim 41 (depends on 1, 22)

A method according to claim 22, wherein said compound according to claim 1 is administered to said patient in a unit dosage form comprising from about 0.05 mg to about 1000 mg of said compound.

### Claim 42 (depends on 23)

A method according to claim 23, wherein said additional therapeutically active compound is selected from antidiabetic agents, antihyperlipidemic agents, antiobesity agents, antihypertensive agents and agents for the treatment of complications resulting from, or associated with, diabetes.

### Claim 43 (depends on 1, 23)

A method according to claim 23, wherein said compound according to claim 1 is administered to said patient in a unit dosage form comprising from about 0.05 mg to about 1000 mg of said compound.

### Claim 44 (depends on 24)

A method according to claim 24, wherein said additional therapeutically active compound is selected from antidiabetic agents, antihyperlipidemic agents, antiobesity agents, antihypertensive agents and agents for the treatment of complications resulting from, or associated with, diabetes.

### Claim 45 (depends on 1, 24)

A method according to claim 24, wherein said compound according to claim 1 is administered to said patient in a unit dosage form comprising from about 0.05 mg to about 1000 mg of said compound.

### Claim 46 (depends on 25)

A method according to claim 25, wherein said additional therapeutically active compound is selected from antidiabetic agents, antihyperlipidemic agents, antiobesity agents, antihypertensive agents and agents for the treatment of complications resulting from, or associated with, diabetes.

### Claim 47 (depends on 1, 25)

A method according to claim 25, wherein said compound according to claim 1 is administered to said patient in a unit dosage form comprising from about 0.05 mg to about 1000 mg of said compound.

### Claim 48 (depends on 26)

A method according to claim 26, wherein said additional therapeutically active compound is selected from antidiabetic agents, antihyperlipidemic agents, antiobesity agents, antihypertensive agents and agents for the treatment of complications resulting from, or associated with, diabetes.

### Claim 49 (depends on 1, 26)

A method according to claim 26, wherein said compound according to claim 1 is administered to said patient in a unit dosage form comprising from about 0.05 mg to about 1000 mg of said compound.

### Claim 50 (depends on 27)

A method according to claim 27 wherein said additional therapeutically active compound is selected from antidiabetic agents, antihyperlipidemic agents, antiobesity agents, antihypertensive agents and agents for the treatment of complications resulting from, or associated with, diabetes.

### Claim 51 (depends on 1, 27)

A method according to claim 27, wherein said compound according to claim 1 is administered to said patient in a unit dosage form comprising from about 0.05 mg to about 1000 mg of said compound.

### Claim 52 (depends on 28)

A method according to claim 28, wherein said additional therapeutically active compound is selected from antidiabetic agents, antihyperlipidemic agents, antiobesity agents, antihypertensive agents and agents for the treatment of complications resulting from, or associated with, diabetes.

### Claim 53 (depends on 1, 28)

A method according to claim 28, wherein said compound according to claim 1 is administered to said patient in a unit dosage form comprising from about 0.05 mg to about 1000 mg of said compound.

### Claim 54 (depends on 29)

A method according to claim 29, wherein said additional therapeutically active compound is selected from antidiabetic agents, antihyperlipidemic agents, antiobesity agents, antihypertensive agents and agents for the treatment of complications resulting from, or associated with, diabetes.

### Claim 55 (depends on 1, 29)

A method according to claim 29, wherein said compound according to claim 1 is administered to said patient in a unit dosage form comprising from about 0.05 mg to about 1000 mg of said compound.

### Claim 56 (depends on 30)

A method according to claim 30, wherein said additional therapeutically active compound is selected from antidiabetic agents, antihyperlipidemic agents, antiobesity agents, antihypertensive agents and agents for the treatment of complications resulting from, or associated with, diabetes.

### Claim 57 (depends on 1, 30)

A method according to claim 30, wherein said compound according to claim 1 is administered to said patient in a unit dosage form comprising from about 0.05 mg to about 1000 mg of said compound.

### Claim 58 (depends on 31)

A method according to claim 31, wherein said additional therapeutically active compound is selected from antidiabetic agents, antihyperlipidemic agents, antiobesity agents, antihypertensive agents and agents for the treatment of complications resulting from, or associated with, diabetes.

### Claim 59 (depends on 1, 31)

A method according to claim 31, wherein said compound according to claim 1 is administered to said patient in a unit dosage form comprising from about 0.05 mg to about 1000 mg of said compound.
